MULTIPLE organ failure (MOF) induced by mesenteric infarction is associated with a high mortality rate. This study reports eicosanoid and cytokine levels in the blood of three atherosclerotic patients who ultimately died from MOF induced by mesenteric infarction. High plasma levels of 6-keto-prostaglandin (PG) $F_{1\alpha}$ (the stable metabolite of PGI_2), interleukin (IL)-6 and IL-8 are observed whereas plasma tumour necrosis factor alpha (TNF α), TxB_2 (the stable metabolite of TxA_2), PGE_2 , leukotrienes (LT) B_4 and LTC $_4$, and whole blood platelet-activating factor levels are not different from values obtained in similarly severe atherosclerotic patients. This short report questioned the clinical involvement of TNF α during such a pathology where a persistent translocation of endotoxin has been observed through the gut endothelial barrier. Activation of phospholipase A_2 is suggested by the increase in the stable metabolite of PGI_2 and might be by itself or through lipidic metabolites, a major systemic stimulus of IL-6 and IL-8 production.

Key words: Interleukin, Leukotriene, Mesenteric infarction, Prostaglandin, Tumour necrosis factor alpha

Eicosanoid and cytokine levels in plasma of patients during mesenteric infarction

N. Nathan,^{1,CA} Y. Denizot² and P. Feiss¹

¹Department of Anaesthesia, CHU Dupuytren, 2 Avenue Martin Luther King, 87042 Limoges, France; and ²Laboratoire d'Hématologie Expérimentale, Faculté de Médecine, 2 Rue du Dr Marcland, 87025 Limoges Cédex, France

^{CA}Corresponding Author
Fax: (+33) 05 55 05 67 92

Introduction

Mesenteric infarction is associated with a high mortality rate. Lactic acidosis, hyperthermia, acute respiratory distress syndrome and cardiogenic shock are common consequences of this disease suggesting the plasma release of factors inducing multiple organ failure (MOF). Eicosanoids [such as prostaglandins (PG) E_2 and I_2 , leukotrienes (LT) B_4 and C_4 and platelet-activating factor (PAF)] and cytokines [such as tumour necrosis factor alpha (TNF α), interleukin (IL)-6 and IL-8] could be involved in this process because of their cardiovascular and proinflammatory effects. Phospholipase A_2 (the enzyme leading to eicosanoid production) is stimulated in experimental mesenteric ischaemia-reperfusion syndrome.¹ On the other hand, in animal and human mesenteric ischaemia, the bacterial translocation might trigger TNF α then IL-6 and IL-8 plasma release.² Finally, the production and action of cytokines and eicosanoids are linked to each other. Thus we have assessed eicosanoid and cytokine plasma levels in three patients with mesenteric infarction before MOF development compared with 10 atherosclerotic patients.

Patients and Methods

The first patient (71 years old) developed a jejunal infarction 48 h after a transurethral resection of the prostate which was complicated by myocardial ischaemia and supraventricular arrhythmia. Treatment included antiarrhythmic drugs (amiodarone and deslanoside), and venous thrombosis prophylaxis with a low molecular weight heparin (dalteparine 5000 IU). At blood sampling, blood pressure (120/80 mmHg) and heart rate (100 cpm) were stable but hyperthermia (38°C), hyperleukocytosis (13 g.l⁻¹) and metabolic acidosis (pH = 7.31, HCO_3^- = 18.1 mmol.l⁻¹) were present. The prothrombin time (10 s) and the platelet count (359 g.l⁻¹) were normal. A cardiogenic shock occurred in the early postoperative period and the patient died 34 days later of a MOF syndrome.

The second patient (87 years old) suffered from angina pectoris, non-insulin-dependent diabetes mellitus and chronic obstructive pulmonary disease. His right leg had been amputated 2 days before and he was taking orally a calcium inhibitor (nifedipine) and transdermal trinitrine. At blood sampling arterial pressure

(120/80 mmHg) and heart rate (85 cpm) were stable but hyperthermia (38.5°C), polypnoea, and severe lactic acidosis ($\text{pH} = 7.15$, $\text{HCO}_3^- = 8.8 \text{ mmol.l}^{-1}$, blood lactates = 14.4 mmol.l^{-1}) were present. Activated partial thrombin time (30.7 s), prothrombin time (14 s) and platelet count (257 g.l^{-1}) were normal. Surgery revealed a partial small bowel necrosis without occlusion of the mesenteric artery and vein. The patient died 19 h later from a severe cardiogenic shock.

The third patient (76 years old) had a mitral prosthesis and atria fibrillation treated by oral anticoagulant (fluidone). At blood sampling, blood pressure (150/80 mmHg) and heart rate (105 cpm) were stable but associated with hyperthermia (39°C), metabolic acidosis ($\text{pH} = 7.38$, $\text{HCO}_3^- = 16 \text{ mmol.l}^{-1}$) and hyperleukocytosis (25.5 g.l^{-1}). Coagulation parameters demonstrated the biological efficiency of the anticoagulant treatment without associated disseminated intravascular coagulation (prothrombin time_{INR} = 19% factor V level = 133%). Laparotomy revealed a necrosis of the whole digestive tract and the patient died 19 h later from cardiogenic shock.

The control patients (mean age 69 [26] years) (eight males/two females) suffered from a severe atherosclerotic disease and were scheduled for coronary artery bypass grafting. Their treatment included trinitrine or calcium inhibitors. All patients had their aspirin and angiotensin converting enzyme inhibitors stopped for 1 week and 3 days respectively at the time of blood sampling for which they gave written informed consent.

Blood samples were obtained at the time of diagnosis of mesenteric infarction during laparotomy before MOF occurred. Blood PAF was ethanol extracted, processed and assayed by platelet aggregation.³ Plasma PAF acetylhydrolase activity (the enzyme which inactivates PAF)

was measured by the degradation of ³H-PAF.⁴ Cytokines and other eicosanoids were determined in plasma with specific enzyme-immunosorbent assay (EIA) after a three- and five-fold dilution in EIA buffer (TEBU and Cayman Chemicals, sensitivity 2 and 5 pg.ml⁻¹, respectively). The results (shown as individual values and median [range] for the control group) are compared with those of the control patient by a Mann-Whitney *U*-test.

Results and Discussion

The results are presented in Table 1. High plasma IL-6, IL-8 and 6-keto-PGF_{1α} (the stable metabolite of PGI₂) levels were found in these three mesenteric infarcted patients suggesting a role for these mediators in the MOF syndrome which occurred later. High IL-6 and IL-8 levels are associated with a poor prognosis during sepsis syndrome where TNFα is supposed to trigger their synthesis. In these three patients, TNFα was not detectable suggesting that its production was not clinically relevant because it was not as high as during sepsis despite a theoretical persistent endotoxic stimulus.² TNFα independent pathway of IL-6 and IL-8 synthesis have already been described during sepsis as well as during experimentally induced cancer. However, the role of TNFα as a mediator inducing IL-6 and IL-8 synthesis cannot be definitively excluded. Indeed, the fixation of TNFα on soluble receptors and/or its transient release may lead to difficulties in its detection in blood. No elevated blood PAF levels were observed in these patients while PAF is produced by the intestinal tract after experimental hypoxia and PAF antagonists reduced mesenteric ischaemia-induced mortality in animals.⁵ These low PAF levels did not result from an increased PAF degradation as shown by the

Table 1. Blood platelet-activating factor (PAF), plasma TNFα, IL-6, IL-8, LTB₄, LTC₄, 6-keto-PGF_{1α}, TxB₂, PGE₂ (pg.ml⁻¹) and acetylhydrolase activity (nmol.min⁻¹.ml⁻¹) in patients with mesenteric infarction (individual values) compared with atherosclerotic patients (median [range]) by Mann-Whitney *U*-tests

	Patient 1	Patient 2	Patient 3	Control patients (n = 10)	P
TNFα	0	0	0	0 [0]	1
IL-6	980	3800	600	0 [18]	0.01
IL-8	160	210	225	36 [135]	0.01
PAF	175	220	50	113 [49]	0.55
Acetylhydrolase	10.4	51.7	36.0	65.9 [49.3]	0.35
6 keto PGF _{1α}	3400	2600	2300	240 [620]	0.01
TxB ₂	125	450	5	72.5 [500]	0.67
PGE ₂	760	180	1880	220 [848]	0.35
LTB ₄	0	0	0	0 [0]	0.32
LTC ₄	0	0	0	0 [128]	0.26

normal PAF acetylhydrolase activity. The other lipidic mediators were not detectable or were at normal levels except for the stable metabolite of PGI₂ which may be secreted chiefly from vascular endothelium after hypoxia. The levels of TxB₂ in plasma were similar to those of severe atherosclerotic patients. TxA₂ plasma levels are supposed to be originated chiefly from activated platelets. The absence of haemostasis impairment in our patients may, in part, explain the similar values of their TxB₂ blood levels compared with those of atherosclerotic patients. PGI₂ is a potent vasodilator whereas TxA₂ highly vasoconstricts peripheral vessels. The high PGI₂-TxB₂ ratio observed in our patient could be considered as a protective mechanism to counteract the mesenteric hypoperfusion.

The number of subjects in this study is small due to difficulties in obtaining blood before MOF occurrence. Indeed, the diagnosis of mesenteric infarction is usually made late, at the time of MOF. Nevertheless our results confirm experimental data questioning the true role of TNF α induced by endotoxaemia as a trigger

for inflammatory reaction and MOF as it has already been observed during sepsis.⁶ The activation of phospholipase A₂ and the subsequent release of eicosanoids which may in turn stimulate IL-6 or IL-8 production are other ways of research deserving further investigation in humans.

References

1. Koike K, Moore EE, Kim FJW, Carl WS, Banerjee A. Gut phospholipase A₂ mediates neutrophil priming and lung injury after mesenteric ischaemia-reperfusion. *Am J Physiol* 1995; **268**: G397-G403.
2. Gogler H, Meckes P, Beger HG. Endotoxin bei diffuseitriger peritonitis. *Zentralbl Chir* 1985; **110**: 1388-1398.
3. Denizot Y, Trimoreau F, Dupuis F, Verger C, Praloran V. PAF and hematopoiesis III. Presence and metabolism of platelet-activating factor in human bone marrow. *Biochem Biophys Acta* 1995; **1265**: 55-60.
4. Miwa M, Miyaka T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, Araki Y, Matsumoto M. Characterization of serum platelet-activating factor (paf) acetylhydrolase. *J Clin Invest* 1988; **82**: 1983-1991.
5. Filep JG, Braquet P, Mozes T. Interactions between platelet-activating factor and prostanoids during ischemia-reperfusion-induced shock in the anesthetized dog. *Grv Shock* 1991; **35**: 1-8.
6. Koike K, Moore EE, Moore FA, Read RA, Carl VS, Banerjee A. Gut ischemia/reperfusion produces lung injury independent of endotoxin. *Crit Care Med* 1994; **22**: 1438-1444.

Received 13 November 1996;
accepted 5 December 1996